Company intelligence / Profile preview

Global Preventive Medicine Biotech

Hsinchu/Zhubei City, Hsinchu County, Taiwanpmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Development stage: Other

Overview

Bio Preventive Medicine has developed and commercialized the DNlite Test, a non-invasive urinary test for monitoring progression of diabetic nephropathy. The company also develops other biomarker-based diagnostics targeting chronic diseases and cancer. Their products are used to aid early detection, prevention, screening, and monitoring of disease progression.

Therapeutic areas: NephrologyOncologyOther
Modalities: Diagnostic testBiomarker-based diagnostic technology
Industry: Protein Biomarker Diagnostics

Partnerships

The company has established pharmaceutical partnerships to validate clinical trial efficiency in drug development using their biomarkerscollaborates with leading industry organizations on assay platform development

Beyond the preview

Go deeper on Global Preventive Medicine Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Global Preventive Medicine Biotech.

Explore the full profile